While all publicly traded enterprises aim for business success, achieving it can also ironically lead to valuation pressures. That's the tough lesson that pharmaceutical giant Gilead Sciences, Inc. (NASDAQ:GILD) learned the hard way recently. Although the company delivered the goods for its latest financial disclosure, post-earnings digestion appears to have negatively impacted GILD stock. Nevertheless, the red ink presents a potential opportunity for bullish speculators.
On paper, the print was impressive. For the second quarter, Gilead Sciences posted earnings per share of $2.01, beating Wall Street analysts' consensus target of $1.94. The latest figure matched the year-ago quarter's result. On the top line, the pharmaceutical firm generated $7.08 billion, up 1.77% from analysts' consensus view of $6.94 billion. Further, the latest tally was an improvement over the prior year's print of $6.95 billion.
